OLN Stock Analysis: Olin | NYSE
Chemicals | NYSE, USA | Market Cap: 1.940m USD | 12M Return: -30.1% | US6806652052 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 46.6M
Qual. Beats: 0
Rev. Trend: -23.4%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Olin Corporation is a U.S.-based commodity chemicals manufacturer that also produces sporting and military ammunition. The company operates through three segments: Chlor Alkali Products and Vinyls (chlorine, caustic soda, EDC/VCM, methyl chloride, bleach, and related intermediates), Epoxy (allyl chloride, epichlorohydrin, acetone, phenol, bisphenol, and liquid/solid epoxy resins), and Winchester (shotshells, centerfire and rimfire ammunition, small caliber military rounds, and industrial powder-actuated tool loads).
Distribution spans the United States, Europe, Asia Pacific, the Middle East, Africa, India, Latin America, and Canada. Chemical products are sold through a direct sales force to industrial customers, mass merchants, retailers, wholesalers, and other distributors. Winchester products reach end users through gun clubs, retailers, wholesalers, the U.S. Government and its prime contractors, and law enforcement agencies. The company was incorporated in 1892 and is headquartered in Clayton, Missouri.
Olin operates within the GICS Materials sector (Commodity Chemicals sub-industry), a capital-intensive and cyclical segment where margins are heavily influenced by energy and feedstock costs, plant utilization, and global supply-demand balances. The Winchester ammunition business is atypical for a commodity chemicals issuer, providing a more consumer-facing revenue stream that often exhibits different demand drivers than the chemical segments.
- Chlor-alkali ECU pricing tracks housing and industrial demand cycles
- Winchester ammunition revenue grows on hunting demand and military contracts
- Epoxy margins pressured by Asia competition and resin oversupply
| Net Income: -139.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -2.18 > 1.0 |
| NWC/Revenue: 9.62% < 20% (prev 11.12%; Δ -1.50% < -1%) |
| CFO/TA 0.04 > 3% & CFO 307.2m > Net Income -139.0m |
| Net Debt (3.61b) to EBITDA (487.8m): 7.40 < 3 |
| Current Ratio: 1.42 > 1.5 & < 3 |
| Outstanding Shares: last quarter (113.9m) vs 12m ago -1.73% < -2% |
| Gross Margin: 6.87% > 18% (prev 8.69%; Δ -1.82% > 0.5%) |
| Asset Turnover: 88.73% > 50% (prev 86.90%; Δ 1.84% > 0%) |
| Interest Coverage Ratio: -0.06 > 6 (EBIT TTM -11.0m / Interest Expense TTM 180.5m) |
| A: 0.09 (Total Current Assets 2.19b - Total Current Liabilities 1.54b) / Total Assets 7.44b |
| B: 0.27 (Retained Earnings 2.00b / Total Assets 7.44b) |
| C: -0.00 (EBIT TTM -11.0m / Avg Total Assets 7.55b) |
| D: 0.30 (Book Value of Equity 1.71b / Total Liabilities 5.73b) |
| Altman-Z'' = 1.75 = BBB |
| DSRI: 0.97 (Receivables 1.04b/1.07b, Revenue 6.70b/6.66b) |
| GMI: 1.26 (GM 8.69% / 6.87%) |
| AQI: 1.02 (AQ_t 0.38 / AQ_t-1 0.37) |
| SGI: 1.01 (Revenue 6.70b / 6.66b) |
| TATA: -0.06 (NI -139.0m - CFO 307.2m) / TA 7.44b) |
| Beneish M = -2.81 (Cap -4..+1) = A |
As of September 20, 2026, the stock is trading at USD 16.84 with a total of 3,943,623 shares traded. Over the past week, the price has changed by -2.09%, over one month by -7.82%, over three months by -22.61% and over the past year by -30.08%.
Current recommended Stop Loss: 15.90 (which is 5.6% or 1.4 ATR below the current price).
Olin has received a consensus analysts rating of 3.25. Therefore, it is recommended to hold OLN.
- StrongBuy: 3
- Buy: 0
- Hold: 12
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 21.7 | 29% |
P/E Forward = 26.3852
P/S = 0.2894
P/B = 1.1416
P/EG = 7.0492
Revenue TTM = 6.70b USD
EBIT TTM = -11.0m USD
EBITDA TTM = 487.8m USD
Long Term Debt = 3.03b USD (from longTermDebt, last quarter)
Short Term Debt = 73.0m USD (from shortTermDebt, last quarter)
Debt = 3.79b USD (from shortLongTermDebtTotal, last quarter) + Leases 378.4m
Net Debt = 3.61b USD (calculated: Debt 3.79b - CCE 177.4m)
Enterprise Value = 5.55b USD (1.94b + Debt 3.79b - CCE 177.4m)
Interest Coverage Ratio = -0.06 (Ebit TTM -11.0m / Interest Expense TTM 180.5m)
EV/FCF = 55.15x (Enterprise Value 5.55b / FCF TTM 100.6m)
FCF Yield = 1.81% (FCF TTM 100.6m / Enterprise Value 5.55b)
FCF Margin = 1.50% (FCF TTM 100.6m / Revenue TTM 6.70b)
Net Margin = -2.07% (Net Income TTM -139.0m / Revenue TTM 6.70b)
Gross Margin = 6.87% ((Revenue TTM 6.70b - Cost of Revenue TTM 6.24b) / Revenue TTM)
Gross Margin QoQ = 9.77% (prev 4.79%)
Tobins Q-Ratio = 0.75 (Enterprise Value 5.55b / Total Assets 7.44b)
Interest Expense / Debt = 4.77% (Interest Expense 180.5m / Debt 3.79b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -8.69m (EBIT -11.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.42 (Total Current Assets 2.19b / Total Current Liabilities 1.54b)
Debt / Equity = 2.21 (Debt 3.79b / totalStockholderEquity, last quarter 1.71b)
Debt / EBITDA = 7.40 (Net Debt 3.61b / EBITDA 487.8m)
Debt / FCF = 35.87 (Net Debt 3.61b / FCF TTM 100.6m)
Total Stockholder Equity = 1.81b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.84% (Net Income -139.0m / Total Assets 7.44b)
RoE = -7.67% (Net Income TTM -139.0m / Total Stockholder Equity 1.81b)
RoCE = -0.23% (EBIT -11.0m / Capital Employed (Equity 1.81b + L.T.Debt 3.03b))
RoIC = -0.15% (negative operating profit) (NOPAT -8.69m / Invested Capital 5.79b)
WACC = 5.67% (E(1.94b)/V(5.73b) * Re(9.38%) + D(3.79b)/V(5.73b) * Rd(4.77%) * (1-Tc(0.21)))
Discount Rate = 9.38% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -92.92 | Cagr: -2.97%
[DCF] Terminal Value 73.10% ; FCFF base≈168.8m ; Y1≈148.1m ; Y5≈119.6m
[DCF] Fair Price = N/A (negative equity: EV 1.92b - Net Debt 3.61b = -1.69b; debt exceeds intrinsic value)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: -23.37 | Revenue CAGR: -0.72% | SUE: -0.92 | # QB: -1
EPS current Quarter (2026-09-30): EPS=0.19 | Chg30d=-4.50% | Revisions=-44% | Analysts=6
EPS current Year (2026-12-31): EPS=-0.46 | Chg30d=+1.29% | Revisions=-67% | GrowthEPS=-98.7% | GrowthRev=+2.8%
EPS next Year (2027-12-31): EPS=0.79 | Chg30d=-0.34% | Revisions=-12% | GrowthEPS=+271.7% | GrowthRev=+4.6%
[Analyst] Revisions Ratio: -55% (up=3, down=14)